Complications Associated with Recombinant Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke

E-ISSN： 1996-3181|12|2|155-169

ISSN： 1871-5273

Source： CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol.12, Iss.2, 2013-04, pp. : 155-169

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost-Utility Analysis of Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke: A Canadian Healthcare Perspective

By Sinclair S.E.

PharmacoEconomics, Vol. 19, Iss. 9, 2001-01 ,pp. : 927-936

Adis International

Access to resources Recommend Favorite

Tissue-type plasminogen activator as a therapeutic target in stroke

By Gravanis Iordanis Tsirka Stella E

Expert Opinion on Therapeutic Targets, Vol. 12, Iss. 2, 2008-02 ,pp. : 159-170

Informa Healthcare

Access to resources Recommend Favorite

Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator (rt-PA) in Acute Lower Limb Ischaemia

By Flis V Kobilica N Bergauer A Mrdža B Milotič F Štirn B

The Journal of International Medical Research, Vol. 39, Iss. 3, 2011-05 ,pp. : 1107-1112

Field House Publishing

Access to resources Recommend Favorite

Vascular Protection to Increase the Safety of Tissue Plasminogen Activator for Stroke

Current Pharmaceutical Design, Vol. 18, Iss. 25, 2012-07 ,pp. : 3677-3684

Bentham Science Publishers

Access to resources Recommend Favorite

Optimal Timing of Thrombolytic Therapy in Acute Ischaemic Stroke

By Madden K.

CNS Drugs, Vol. 16, Iss. 4, 2002-01 ,pp. : 213-218

Adis International

Access to resources Recommend Favorite